Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Xenon Pharmaceuticals Inc. (XENE)
USD67.72
-1.20 (-1.74%)
CA NASDAQ Healthcare Biotechnology
Address
3650 Gilmore Way V5G 4W8
Burnaby, BC, CA
Burnaby, BC, CA
CEO
Andrea DiFabio
Website
xenon-pharma.com
IPO
2014-11-05
CIK 1582313 ISIN CA98420N1050
Description
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD67.72
-1.20 (-1.74%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
0.61
Float Shares
78.42M
Free Float %
99.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.40% | -5.58% | -5.82% | +32.15% | +38.61% | +22.71% | +53.42% | +36.95% | +215.55% | +725.83% | +423.81% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (22 ratings, all time)
Buy
Price Targets & DCF
Current price
67.72
Low
60.00
-11.4%
Consensus
85.00
+25.5%
Median
89.50
+32.2%
High
100.00
+47.7%
DCF (Unlevered)
2.45
-96.4%
DCF (Levered)
2.33
-96.6%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 17 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 10 |
83.40
+23.2%
|
| Last Year | 13 |
76.23
+12.6%
|
| All Time | 26 |
62.50
-7.7%
|
Quality scores
Altman Z-Score
52.54
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
2 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%— Q1'26: -100.0% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-44.9% Q1'26: -41.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-4,530.8%
-
EBIT margin Biotechnology: +0.0%-4,598.6%
-
ROIC Biotechnology: -16.1%-845.0% Q1'26: -174.9% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+1.7% ★ Q1'26: +11.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.02× Q1'26: -0.02× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 8 Rev. Ana. 15 EPS Ana. |
Dec 2027 10 Rev. Ana. 14 EPS Ana. |
Dec 2028 15 Rev. Ana. 13 EPS Ana. |
Dec 2029 11 Rev. Ana. 11 EPS Ana. |
Dec 2030 7 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
15.58M
est: 16.98M (-8.3%)
|
1.80M
est: 1.92M (-5.9%)
|
311.0K
est: 12.80M (-97.6%)
|
6.83M
est: 3.50M (+95.1%)
|
32.17M
est: 30.22M (+6.5%)
|
18.44M
est: 20.72M (-11.0%)
|
9.43M
est: 12.16M (-22.4%)
|
—
est: 2.20M (-100.0%)
|
—
est: 312.5K (-100.0%)
|
7.50M
est: 7.58M (-1.1%)
|
3.54M
2.05M – 5.63M
-53.4% YoY
|
61.25M
19.72M – 119.68M
+1,632.0% YoY
|
277.53M
275.40M – 279.67M
+353.1% YoY
|
781.68M
452.60M – 1.24B
+181.7% YoY
|
1.21B
699.40M – 1.92B
+54.5% YoY
|
| EBITDA |
-8.32M
est: -2.95M (-181.9%)
|
-23.95M
est: -333.3K (-7,087.7%)
|
-30.06M
est: -2.23M (-1,250.8%)
|
-39.76M
est: -608.6K (-6,432.2%)
|
-27.97M
est: -5.25M (-432.3%)
|
-78.09M
est: -3.60M (-2,067.4%)
|
-127.74M
est: -2.11M (-5,941.1%)
|
-210.51M
est: -382.1K (-54,993.0%)
|
-235.86M
est: -62.5K (-377,280.4%)
|
-342.35M
est: -1.52M (-22,472.6%)
|
-707.2K
-1.13M – -409.5K
+53.4% YoY
|
-12.25M
-23.94M – -3.94M
-1,632.0% YoY
|
-55.51M
-55.93M – -55.08M
-353.1% YoY
|
-156.34M
-248.94M – -90.52M
-181.7% YoY
|
-241.58M
-384.69M – -139.88M
-54.5% YoY
|
| EBIT |
-9.36M
est: -3.02M (-209.9%)
|
-24.82M
est: -340.9K (-7,179.3%)
|
-30.70M
est: -2.28M (-1,248.9%)
|
-40.18M
est: -622.6K (-6,354.1%)
|
-28.61M
est: -5.38M (-432.3%)
|
-78.99M
est: -3.69M (-2,043.2%)
|
-129.14M
est: -2.16M (-5,870.1%)
|
-214.05M
est: -390.9K (-54,658.7%)
|
-238.42M
est: -62.5K (-381,376.5%)
|
-344.89M
est: -1.52M (-22,640.3%)
|
-707.2K
-1.13M – -409.5K
+53.4% YoY
|
-12.25M
-23.94M – -3.94M
-1,632.0% YoY
|
-55.51M
-55.93M – -55.08M
-353.1% YoY
|
-156.34M
-248.94M – -90.52M
-181.7% YoY
|
-241.58M
-384.69M – -139.88M
-54.5% YoY
|
| Net Income |
-15.75M
est: -77.12M (+79.6%)
|
-23.00M
est: -118.98M (+80.7%)
|
-30.70M
est: -115.80M (+73.5%)
|
-41.60M
est: -126.97M (+67.2%)
|
-28.84M
est: -67.88M (+57.5%)
|
-78.88M
est: -129.15M (+38.9%)
|
-125.37M
est: -164.12M (+23.6%)
|
-182.39M
est: -199.06M (+8.4%)
|
-234.33M
est: -252.90M (+7.3%)
|
-345.91M
est: -333.01M (-3.9%)
|
-374.48M
-402.75M – -346.21M
-12.5% YoY
|
-419.55M
-488.47M – -285.81M
-12.0% YoY
|
-278.70M
-485.91M – 128.72M
+33.6% YoY
|
107.95M
48.87M – 191.07M
+138.7% YoY
|
371.41M
168.14M – 657.41M
+244.1% YoY
|
| SGA |
9.79M
est: 24.01M (-59.2%)
|
6.79M
est: 2.71M (+150.6%)
|
7.31M
est: 18.10M (-59.6%)
|
10.80M
est: 4.95M (+118.2%)
|
12.94M
est: 42.74M (-69.7%)
|
21.97M
est: 29.30M (-25.0%)
|
32.81M
est: 17.20M (+90.8%)
|
46.54M
est: 3.11M (+1,397.5%)
|
68.90M
est: 1.08M (+6,277.5%)
|
79.63M
est: 26.22M (+203.7%)
|
12.23M
7.08M – 19.47M
-53.4% YoY
|
211.75M
68.17M – 413.77M
+1,632.0% YoY
|
959.54M
952.15M – 966.92M
+353.1% YoY
|
2.70B
1.56B – 4.30B
+181.7% YoY
|
4.18B
2.42B – 6.65B
+54.5% YoY
|
| EPS |
-1.10
est: -0.99 (-11.1%)
|
-1.48
est: -1.53 (+3.1%)
|
-1.71
est: -1.49 (-15.0%)
|
-1.54
est: -1.63 (+5.5%)
|
-0.83
est: -0.87 (+4.8%)
|
-1.77
est: -1.66 (-6.8%)
|
-2.06
est: -2.09 (+1.2%)
|
-2.73
est: -2.83 (+3.4%)
|
-3.01
est: -3.10 (+2.8%)
|
-4.36
est: -4.25 (-2.7%)
|
-4.72
-5.08 – -4.37
-11.1% YoY
|
-4.81
-6.16 – -3.61
-1.9% YoY
|
-3.08
-6.13 – 1.62
+35.9% YoY
|
1.36
0.62 – 2.41
+144.2% YoY
|
4.69
2.12 – 8.30
+244.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-344.15M
OE per share TTM
-4.23
Owner's Yield
-7.04%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
123.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
56
Total invested
158.61M
Insider transactions (90d)
0
Beneficial owners (>5%)
33
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Avoro Capital Advisors LLC | 4.99M | 9.70% | 4.99M | — | 4.99M | — | IA, OO | Delaware | 2022-02-11 | ↗ |
| 2 | Behzad Aghazadeh | 4.99M | 9.70% | 4.99M | — | 4.99M | — | IN | Delaware | 2022-02-11 | ↗ |
| 3 | Wellington Group Holdings LLP | 4.16M | 5.56% | — | 3.91M | — | — | HC | Massachusetts | 2024-02-08 | ↗ |
| 4 | Wellington Investment Advisors Holdings LLP | 4.16M | 5.56% | — | 3.91M | — | — | HC | Massachusetts | 2024-02-08 | ↗ |
| 5 | Wellington Management Group LLP | 4.16M | 5.56% | — | 3.91M | — | — | HC | Massachusetts | 2024-02-08 | ↗ |
| 6 | Wellington Management Company LLP | 4.04M | 5.40% | — | 3.89M | — | — | IA | Massachusetts | 2024-02-08 | ↗ |
| 7 | DRIEHAUS CAPITAL MANAGEMENT LLC | 3.12M | 6.05% | — | 3.12M | — | 3.12M | IA | — | 2022-02-14 | ↗ |
| 8 | Steven A. Cohen | 3.01M | 4.00% | — | 3.01M | — | 3.01M | IN | Delaware | 2022-02-14 | ↗ |
| 9 | Point72 Asset Management, L.P. | 2.99M | 4.00% | — | 2.99M | — | 2.99M | PN | Delaware | 2022-02-14 | ↗ |
| 10 | Point72 Capital Advisors, Inc. | 2.99M | 4.00% | — | 2.99M | — | 2.99M | CO | Delaware | 2022-02-14 | ↗ |
| 11 | venBio Select Advisor LLC | 2.40M | 9.50% | 2.40M | — | 2.40M | — | IA, OO | Delaware | 2019-02-14 | ↗ |
| 12 | SMALLCAP World Fund, Inc. | 1.90M | 7.50% | — | — | — | — | IV | Maryland | 2019-02-14 | ↗ |
| 13 | BVF Inc. | 1.78M | 12.30% | — | 1.78M | — | — | CO | Delaware | 2016-03-18 | ↗ |
| 14 | BVF Partners L.P. | 1.78M | 12.30% | — | 1.78M | — | — | IA, PN | Delaware | 2016-03-18 | ↗ |
| 15 | Mark N. Lampert | 1.78M | 12.30% | — | 1.78M | — | — | IN | Delaware | 2016-03-18 | ↗ |
| 16 | Capital World Investors ** | 1.43M | 7.90% | 1.43M | — | 1.43M | — | IA | Delaware | 2018-02-14 | ↗ |
| 17 | Teva Canada Limited | 1.11M | 7.70% | — | 1.11M | — | — | CO | Israel | 2016-03-30 | ↗ |
| 18 | Teva Pharmaceutical Industries Limited | 1.11M | 7.70% | — | 1.11M | — | — | CO | Israel | 2016-03-30 | ↗ |
| 19 | Vivo Opportunity, LLC | 1.05M | 5.60% | 1.05M | — | 1.05M | — | OO | OR PLACE OF ORGANIZATION | 2018-07-13 | ↗ |
| 20 | OrbiMed Capital GP VI LLC | 1.00M | 5.59% | — | 1.00M | — | — | OO | Delaware | 2017-02-13 | ↗ |
| 21 | Samuel D. Isaly | 1.00M | 5.59% | — | 1.00M | — | — | IN | United States | 2017-02-13 | ↗ |
| 22 | Biotechnology Value Fund, L.P. | 767.2K | 5.30% | — | 767.2K | — | — | PN | Delaware | 2016-03-18 | ↗ |
| 23 | Adage Capital Advisors, L.L.C. | 665.0K | 1.29% | — | 665.0K | — | — | OO | Delaware | 2022-02-10 | ↗ |
| 24 | Adage Capital Partners GP, L.L.C. | 665.0K | 1.29% | — | 665.0K | — | — | OO | Delaware | 2022-02-10 | ↗ |
| 25 | Adage Capital Partners, L.P. | 665.0K | 1.29% | — | 665.0K | — | — | PN | Delaware | 2022-02-10 | ↗ |
| 26 | Phillip Gross | 665.0K | 1.29% | — | 665.0K | — | — | IN | United States | 2022-02-10 | ↗ |
| 27 | Robert Atchinson | 665.0K | 1.29% | — | 665.0K | — | — | IN | United States | 2022-02-10 | ↗ |
| 28 | OrbiMed Capital LLC | 631.0K | 1.22% | 631.0K | — | 631.0K | — | OO | Delaware | 2022-02-11 | ↗ |
| 29 | Biotechnology Value Fund II, L.P. | 494.7K | 3.40% | — | 494.7K | — | — | PN | Delaware | 2016-03-18 | ↗ |
| 30 | BVF Partners OS Ltd. | 152.7K | 1.10% | — | 152.7K | — | — | CO | Delaware | 2016-03-18 | ↗ |
| 31 | Biotechnology Value Trading Fund OS LP | 152.7K | 1.10% | — | 152.7K | — | — | PN | Delaware | 2016-03-18 | ↗ |
| 32 | Cubist Systematic Strategies, LLC | 14.5K | 4.00% | — | 14.5K | — | 14.5K | OO | Delaware | 2022-02-14 | ↗ |
| 33 | OrbiMed Advisors LLC | — | 0.00% | — | — | — | — | IA | Delaware | 2022-02-11 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
56
-205 vs prev Q
New positions
14
Closed positions
209
Increased
36
Reduced
10
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 597.1K +597.1K (+100.0%) | 26.76B +26.8B (+100.0%) | 0.75% +0.753 pp | 6.61% +6.612 pp | USD44.82 +0.0% | 1 qtrs NEW |
| 2 | FMR LLC | 8.92M +1.3K (+0.0%) | 399.81M +41.7M (+11.6%) | 11.26% -0.040 pp | 0.02% +0.002 pp | USD30.94 +44.9% | 24 qtrs — |
| 3 | AVORO CAPITAL ADVISORS LLC | 5.42M +24.4K (+0.5%) | 243.12M +26.3M (+12.1%) | 6.84% +0.005 pp | 2.34% -0.465 pp | USD21.61 +107.4% | 31 qtrs — |
| 4 | BLACKROCK, INC. | 5.10M +329.3K (+6.9%) | 228.59M +37.0M (+19.3%) | 6.44% +0.393 pp | 0.00% +0.001 pp | USD35.04 +27.9% | 6 qtrs — |
| 5 | WELLINGTON MANAGEMENT GROUP LLP | 4.76M +1.2M (+32.0%) | 213.56M +68.6M (+47.3%) | 6.01% +1.440 pp | 0.04% +0.012 pp | USD42.13 +6.4% | 12 qtrs — |
| 6 | DRIEHAUS CAPITAL MANAGEMENT LLC | 4.54M +369.6K (+8.9%) | 203.42M +36.0M (+21.5%) | 5.73% +0.447 pp | 1.38% +0.183 pp | USD28.75 +55.9% | 24 qtrs — |
| 7 | JANUS HENDERSON GROUP PLC | 4.08M +140.1K (+3.6%) | 183.11M +24.8M (+15.7%) | 5.15% +0.158 pp | 0.08% +0.010 pp | USD38.76 +15.6% | 16 qtrs — |
| 8 | CAPITAL INTERNATIONAL INVESTORS | 3.41M +233.5K (+7.3%) | 153.06M +25.3M (+19.8%) | 4.31% +0.280 pp | 0.02% +0.003 pp | USD29.47 +52.1% | 30 qtrs — |
| 9 | POLAR CAPITAL HOLDINGS PLC | 2.47M -81.1K (-3.2%) | 110.51M +8.3M (+8.1%) | 3.11% -0.114 pp | 0.43% -0.065 pp | USD33.12 +35.3% | 17 qtrs — |
| 10 | BRAIDWELL LP | 1.83M -1.8M (-49.4%) | 81.80M -62.9M (-43.5%) | 2.30% -2.263 pp | 2.62% -1.679 pp | USD36.31 +23.4% | 13 qtrs — |
| 11 | COMMODORE CAPITAL LP | 1.80M -900.0K (-33.3%) | 80.68M -27.7M (-25.6%) | 2.27% -1.148 pp | 5.37% +0.078 pp | USD31.46 +42.5% | 21 qtrs — |
| 12 | ALLIANCEBERNSTEIN L.P. | 1.59M -60.6K (-3.7%) | 71.43M +5.0M (+7.5%) | 2.01% -0.084 pp | 0.02% +0.002 pp | USD37.12 +20.7% | 19 qtrs — |
| 13 | JPMORGAN CHASE & CO | 1.49M +95.0K (+6.8%) | 66.96M +10.8M (+19.2%) | 1.89% +0.113 pp | 0.00% +0.001 pp | USD39.67 +13.0% | 30 qtrs — |
| 14 | STATE STREET CORP | 1.49M +26.1K (+1.8%) | 66.90M +8.0M (+13.6%) | 1.88% +0.026 pp | 0.00% +0.000 pp | USD31.31 +43.1% | 30 qtrs — |
| 15 | CITADEL ADVISORS LLC | 1.32M +362.1K (+37.8%) | 59.22M +20.7M (+53.8%) | 1.67% +0.452 pp | 0.01% +0.003 pp | USD40.92 +9.5% | 30 qtrs — |
| 16 | JENNISON ASSOCIATES LLC | 1.29M +156.8K (+13.8%) | 57.91M +12.3M (+27.1%) | 1.63% +0.193 pp | 0.03% +0.008 pp | USD41.64 +7.6% | 11 qtrs — |
| 17 | HOLOCENE ADVISORS, LP | 1.28M -694.5K (-35.1%) | 57.46M -21.9M (-27.6%) | 1.62% -0.886 pp | 0.12% -0.060 pp | USD32.05 +39.8% | 3 qtrs — |
| 18 | AFFINITY ASSET ADVISORS, LLC | 1.25M -150.0K (-10.7%) | 56.03M -185.0K (-0.3%) | 1.58% -0.196 pp | 3.19% -1.704 pp | USD39.26 +14.2% | 13 qtrs — |
| 19 | WESTFIELD CAPITAL MANAGEMENT CO LP | 1.23M +20.7K (+1.7%) | 54.98M +6.6M (+13.5%) | 1.55% +0.020 pp | 0.23% +0.026 pp | USD39.46 +13.6% | 9 qtrs — |
| 20 | BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. | 1.06M +390.0K (+58.2%) | 47.52M +20.6M (+76.6%) | 1.34% +0.489 pp | 0.05% -0.015 pp | USD42.16 +6.3% | 8 qtrs — |
| 21 | GEODE CAPITAL MANAGEMENT, LLC | 952.7K -24.8K (-2.5%) | 42.69M +3.5M (+8.8%) | 1.20% -0.036 pp | 0.00% +0.000 pp | USD31.13 +44.0% | 29 qtrs — |
| 22 | PRICE T ROWE ASSOCIATES INC /MD/ | 862.3K +820.6K (+1,968.3%) | 38.65M +37.0M (+2,207.5%) | 1.09% +1.035 pp | 0.00% +0.004 pp | USD44.20 +1.4% | 3 qtrs — |
| 23 | SIREN, L.L.C. | 812.8K +— (+0.0%) | 36.43M +3.8M (+11.6%) | 1.03% -0.004 pp | 1.09% -0.190 pp | USD38.58 +16.2% | 6 qtrs — |
| 24 | FIRST TURN MANAGEMENT, LLC | 799.7K +— (+0.0%) | 35.84M +3.7M (+11.6%) | 1.01% -0.004 pp | 4.10% -0.726 pp | USD42.06 +6.6% | 9 qtrs — |
| 25 | ROCK SPRINGS CAPITAL MANAGEMENT LP | 787.8K -64.0K (-7.5%) | 35.31M +1.1M (+3.2%) | 0.99% -0.085 pp | 1.81% -0.188 pp | USD24.02 +86.6% | 24 qtrs — |
| 26 | FRANKLIN RESOURCES INC | 758.1K +62.2K (+8.9%) | 33.98M +6.0M (+21.6%) | 0.96% +0.075 pp | 0.01% +0.001 pp | USD38.88 +15.3% | 12 qtrs — |
| 27 | ABRDN PLC | 750.3K +171.1K (+29.6%) | 33.63M +10.4M (+44.6%) | 0.95% +0.213 pp | 0.05% +0.015 pp | USD38.35 +16.9% | 9 qtrs — |
| 28 | GOLDMAN SACHS GROUP INC | 696.0K -24.6K (-3.4%) | 31.20M +2.3M (+7.8%) | 0.88% -0.035 pp | 0.00% +0.000 pp | USD36.57 +22.6% | 29 qtrs — |
| 29 | FIERA CAPITAL CORP | 686.1K +166.1K (+31.9%) | 30.75M +9.9M (+47.3%) | 0.87% +0.207 pp | 0.10% +0.030 pp | USD40.06 +11.9% | 11 qtrs — |
| 30 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 685.1K -150.0K (-18.0%) | 30.71M -2.8M (-8.4%) | 0.86% -0.193 pp | 0.05% -0.007 pp | USD35.31 +26.9% | 31 qtrs — |
| 31 | AMERICAN CENTURY COMPANIES INC | 680.5K +21.2K (+3.2%) | 30.50M +4.0M (+15.2%) | 0.86% +0.024 pp | 0.02% +0.002 pp | USD31.72 +41.3% | 3 qtrs — |
| 32 | FEDERATED HERMES, INC. | 672.2K +439.7K (+189.1%) | 30.13M +20.8M (+222.8%) | 0.85% +0.554 pp | 0.05% +0.034 pp | USD44.53 +0.7% | 9 qtrs — |
| 33 | VANGUARD GROUP INC | 664.6K -186.7K (-21.9%) | 29.79M -4.4M (-12.9%) | 0.84% -0.240 pp | 0.00% 0.000 pp | USD30.71 +45.9% | 23 qtrs — |
| 34 | CAPITAL WORLD INVESTORS | 655.7K +— (+0.0%) | 29.39M +3.1M (+11.6%) | 0.83% -0.003 pp | 0.00% +0.000 pp | USD26.89 +66.7% | 45 qtrs — |
| 35 | MILLENNIUM MANAGEMENT LLC | 635.1K -749.0K (-54.1%) | 28.46M -27.1M (-48.8%) | 0.80% -0.952 pp | 0.01% -0.012 pp | USD35.41 +26.6% | 25 qtrs — |
| 36 | PICTET ASSET MANAGEMENT HOLDING SA | 626.0K -636.6K (-50.4%) | 28.01M -22.6M (-44.6%) | 0.79% -0.809 pp | 0.03% -0.022 pp | USD34.90 +28.4% | 10 qtrs — |
| 37 | LOOMIS SAYLES & CO L P | 612.0K -28.6K (-4.5%) | 27.43M +1.7M (+6.6%) | 0.77% -0.039 pp | 0.03% +0.003 pp | USD39.05 +14.8% | 13 qtrs — |
| 38 | BARCLAYS PLC | 601.0K +586.0K (+3,908.3%) | 26.94M +26.3M (+4,463.2%) | 0.76% +0.739 pp | 0.01% +0.006 pp | USD44.51 +0.7% | 12 qtrs — |
| 39 | VESTAL POINT CAPITAL, LP | 600.0K -500.0K (-45.5%) | 26.89M -17.3M (-39.1%) | 0.76% -0.636 pp | 0.91% -1.080 pp | USD35.90 +24.8% | 9 qtrs — |
| 40 | CALIGAN PARTNERS LP | 549.7K +549.7K (+100.0%) | 24.64M +24.6M (+100.0%) | 0.69% +0.694 pp | 2.03% +2.028 pp | USD44.82 +0.0% | 1 qtrs NEW |
| 41 | T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | 547.6K -51.5K (-8.6%) | 24.55M +490.0K (+2.0%) | 0.69% -0.068 pp | 0.02% +0.001 pp | USD40.68 +10.2% | 9 qtrs — |
| 42 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 542.0K +— (+0.0%) | 24.29M +2.5M (+11.6%) | 0.68% -0.003 pp | 0.31% -0.022 pp | USD31.30 +43.2% | 3 qtrs — |
| 43 | TIMESSQUARE CAPITAL MANAGEMENT, LLC | 532.7K -24.1K (-4.3%) | 23.88M +1.5M (+6.8%) | 0.67% -0.033 pp | 0.36% +0.040 pp | USD39.89 +12.4% | 13 qtrs — |
| 44 | BIOIMPACT CAPITAL LLC | 485.6K -17.8K (-3.5%) | 21.77M +1.6M (+7.7%) | 0.61% -0.025 pp | 2.49% -0.818 pp | USD38.09 +17.7% | 6 qtrs — |
| 45 | DIMENSIONAL FUND ADVISORS LP | 452.1K -1.9K (-0.4%) | 20.26M +2.0M (+11.2%) | 0.57% -0.005 pp | 0.00% +0.000 pp | USD34.82 +28.7% | 19 qtrs — |
| 46 | ORBIMED ADVISORS LLC | 447.2K +27.6K (+6.6%) | 20.04M +3.2M (+19.0%) | 0.56% +0.033 pp | 0.41% +0.014 pp | USD30.64 +46.3% | 38 qtrs — |
| 47 | NORTHERN TRUST CORP | 438.7K -59.4K (-11.9%) | 19.66M -337.4K (-1.7%) | 0.55% -0.077 pp | 0.00% 0.000 pp | USD31.21 +43.6% | 30 qtrs — |
| 48 | TWO SIGMA INVESTMENTS, LP | 436.7K +436.7K (+100.0%) | 19.57M +19.6M (+100.0%) | 0.55% +0.551 pp | 0.03% +0.028 pp | USD44.82 +0.0% | 1 qtrs NEW |
| 49 | CANDRIAM S.C.A. | 417.4K +20.8K (+5.2%) | 18.71M +2.8M (+17.5%) | 0.53% +0.024 pp | 0.09% +0.010 pp | USD26.04 +72.1% | 19 qtrs — |
| 50 | BANK OF NEW YORK MELLON CORP | 387.2K -31.3K (-7.5%) | 17.35M +553.0K (+3.3%) | 0.49% -0.041 pp | 0.00% 0.000 pp | USD30.48 +47.0% | 27 qtrs — |
| 51 | BAKER BROS. ADVISORS LP | 370.2K +— (+0.0%) | 16.59M +1.7M (+11.6%) | 0.47% -0.002 pp | 0.10% -0.010 pp | USD21.68 +106.7% | 23 qtrs — |
| 52 | DEEP TRACK CAPITAL, LP | 366.4K -833.6K (-69.5%) | 16.42M -31.8M (-65.9%) | 0.46% -1.058 pp | 0.29% -1.052 pp | USD33.67 +33.1% | 5 qtrs — |
| 53 | STEMPOINT CAPITAL LP | 348.6K +156.3K (+81.3%) | 15.62M +7.9M (+102.4%) | 0.44% +0.196 pp | 2.68% +1.132 pp | USD42.24 +6.1% | 5 qtrs — |
| 54 | MORGAN STANLEY | 294.3K -72.2K (-19.7%) | 13.19M -1.5M (-10.4%) | 0.37% -0.093 pp | 0.00% 0.000 pp | USD32.72 +37.0% | 44 qtrs — |
| 55 | CAPTION MANAGEMENT, LLC | 290.0K +230.0K (+383.3%) | 13.00M +10.6M (+439.6%) | 0.37% +0.290 pp | 0.09% +0.070 pp | USD42.02 +6.7% | 3 qtrs — |
| 56 | DAFNA CAPITAL MANAGEMENT LLC | 287.9K +— (+0.0%) | 12.91M +1.3M (+11.6%) | 0.36% -0.001 pp | 3.00% +0.142 pp | USD13.91 +222.2% | 42 qtrs — |
| 57 | DNB ASSET MANAGEMENT AS | 272.8K +23.8K (+9.5%) | 12.23M +2.2M (+22.3%) | 0.34% +0.029 pp | 0.04% +0.005 pp | USD38.74 +15.7% | 13 qtrs — |
| 58 | TWO SIGMA ADVISERS, LP | 259.3K +241.2K (+1,332.7%) | 11.62M +10.9M (+1,499.4%) | 0.33% +0.304 pp | 0.02% +0.021 pp | USD44.62 +0.4% | 10 qtrs — |
| 59 | TUDOR INVESTMENT CORP ET AL | 254.0K +177.2K (+230.6%) | 11.38M +8.3M (+269.1%) | 0.32% +0.223 pp | 0.02% +0.016 pp | USD43.41 +3.2% | 2 qtrs — |
| 60 | NICHOLAS INVESTMENT PARTNERS, LP | 243.0K +123.9K (+104.0%) | 10.89M +6.1M (+127.8%) | 0.31% +0.156 pp | 0.79% +0.428 pp | USD40.94 +9.5% | 13 qtrs — |
| 61 | IRON TRIANGLE PARTNERS LP | 233.7K +233.7K (+100.0%) | 10.47M +10.5M (+100.0%) | 0.29% +0.295 pp | 1.20% +1.198 pp | USD44.82 +0.0% | 1 qtrs NEW |
| 62 | EVERSEPT PARTNERS, LP | 231.4K +231.4K (+100.0%) | 10.37M +10.4M (+100.0%) | 0.29% +0.292 pp | 0.52% +0.523 pp | USD44.82 +0.0% | 1 qtrs NEW |
| 63 | NAN FUNG TRINITY (HK) LTD | 227.0K +68.4K (+43.1%) | 10.17M +3.8M (+59.7%) | 0.29% +0.086 pp | 0.81% +0.170 pp | USD35.37 +26.7% | 3 qtrs — |
| 64 | BANK OF AMERICA CORP /DE/ | 221.4K +22.3K (+11.2%) | 9.92M +1.9M (+24.1%) | 0.28% +0.027 pp | 0.00% +0.000 pp | USD34.62 +29.5% | 25 qtrs — |
| 65 | NUVEEN, LLC | 216.2K -8.1K (-3.6%) | 9.69M +686.6K (+7.6%) | 0.27% -0.011 pp | 0.00% +0.000 pp | USD31.30 +43.2% | 3 qtrs — |
| 66 | STATE OF WISCONSIN INVESTMENT BOARD | 205.6K -2.8K (-1.3%) | 9.21M +847.5K (+10.1%) | 0.26% -0.005 pp | 0.02% +0.001 pp | USD34.64 +29.4% | 16 qtrs — |
| 67 | ADAR1 CAPITAL MANAGEMENT, LLC | 204.0K +14.9K (+7.9%) | 9.14M +1.5M (+20.4%) | 0.26% +0.018 pp | 0.67% -0.042 pp | USD34.32 +30.6% | 7 qtrs — |
| 68 | PERCEPTIVE ADVISORS LLC | 200.8K +— (+0.0%) | 9.00M +937.7K (+11.6%) | 0.25% -0.001 pp | 0.16% -0.072 pp | USD31.46 +42.5% | 20 qtrs — |
| 69 | DEUTSCHE BANK AG\ | 190.2K +77.3K (+68.4%) | 8.53M +4.0M (+88.0%) | 0.24% +0.097 pp | 0.00% +0.001 pp | USD39.86 +12.4% | 13 qtrs — |
| 70 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 189.1K +312.0 (+0.2%) | 8.47M +895.4K (+11.8%) | 0.24% -0.001 pp | 0.00% +0.000 pp | USD31.32 +43.1% | 3 qtrs — |
| 71 | NEW YORK STATE COMMON RETIREMENT FUND | 186.7K +15.0K (+8.7%) | 8.37M +1.5M (+21.4%) | 0.24% +0.018 pp | 0.01% +0.002 pp | USD37.58 +19.3% | 17 qtrs — |
| 72 | NEUBERGER BERMAN GROUP LLC | 178.7K +6.4K (+3.7%) | 8.01M +1.1M (+15.8%) | 0.23% +0.007 pp | 0.01% +0.001 pp | USD35.00 +28.1% | 5 qtrs — |
| 73 | PEREGRINE CAPITAL MANAGEMENT LLC | 174.9K +174.9K (+100.0%) | 7.84M +7.8M (+100.0%) | 0.22% +0.221 pp | 0.24% +0.240 pp | USD44.82 +0.0% | 1 qtrs NEW |
| 74 | JAIN GLOBAL LLC | 173.9K -78.5K (-31.1%) | 7.79M -2.3M (-23.1%) | 0.22% -0.100 pp | 0.04% -0.010 pp | USD40.15 +11.6% | 2 qtrs — |
| 75 | MARSHALL WACE, LLP | 162.6K -449.4K (-73.4%) | 7.29M -17.3M (-70.3%) | 0.21% -0.570 pp | 0.01% -0.018 pp | USD32.04 +39.9% | 19 qtrs — |
| 76 | FORESITE CAPITAL MANAGEMENT IV, LLC | 160.0K +— (+0.0%) | 7.17M +747.2K (+11.6%) | 0.20% -0.001 pp | 3.12% -0.396 pp | USD31.30 +43.2% | 3 qtrs — |
| 77 | LMR PARTNERS LLP | 155.8K +155.8K (+100.0%) | 6.98M +7.0M (+100.0%) | 0.20% +0.197 pp | 0.01% +0.013 pp | USD44.82 +0.0% | 1 qtrs NEW |
| 78 | PARKMAN HEALTHCARE PARTNERS LLC | 154.2K -22.0K (-12.5%) | 6.91M -161.4K (-2.3%) | 0.19% -0.029 pp | 0.66% -0.080 pp | USD28.98 +54.7% | 25 qtrs — |
| 79 | WELLS FARGO & COMPANY/MN | 152.3K +37.1K (+32.2%) | 6.83M +2.2M (+47.6%) | 0.19% +0.046 pp | 0.00% +0.000 pp | USD37.65 +19.0% | 14 qtrs — |
| 80 | NOMURA HOLDINGS INC | 150.0K +150.0K (+100.0%) | 6.72M +6.7M (+100.0%) | 0.19% +0.189 pp | 0.01% +0.009 pp | USD44.82 +0.0% | 1 qtrs NEW |
| 81 | MOORE CAPITAL MANAGEMENT, LP | 140.0K +— (+0.0%) | 6.27M +653.8K (+11.6%) | 0.18% -0.001 pp | 0.09% +0.013 pp | USD40.26 +11.3% | 9 qtrs — |
| 82 | RHENMAN & PARTNERS ASSET MANAGEMENT AB | 139.0K +58.0K (+71.6%) | 6.23M +3.0M (+91.6%) | 0.18% +0.073 pp | 0.58% +0.222 pp | USD41.48 +8.1% | 7 qtrs — |
| 83 | PATIENT SQUARE CAPITAL LP | 136.5K +136.5K (+100.0%) | 6.12M +6.1M (+100.0%) | 0.17% +0.172 pp | 1.31% +1.310 pp | USD44.82 +0.0% | 1 qtrs NEW |
| 84 | REDMILE GROUP, LLC | 133.9K +133.9K (+100.0%) | 6.00M +6.0M (+100.0%) | 0.17% +0.169 pp | 0.44% +0.442 pp | USD44.82 +0.0% | 1 qtrs NEW |
| 85 | ALGERT GLOBAL LLC | 123.2K +68.9K (+127.1%) | 5.52M +3.3M (+153.5%) | 0.16% +0.087 pp | 0.09% +0.050 pp | USD42.87 +4.5% | 16 qtrs — |
| 86 | ASSENAGON ASSET MANAGEMENT S.A. | 119.2K +119.2K (+100.0%) | 5.34M +5.3M (+100.0%) | 0.15% +0.150 pp | 0.01% +0.007 pp | USD44.82 +0.0% | 10 qtrs — |
| 87 | MUTUAL OF AMERICA CAPITAL MANAGEMENT LLC | 116.1K +21.2K (+22.3%) | 5.20M +1.4M (+36.5%) | 0.15% +0.026 pp | 0.05% +0.015 pp | USD34.70 +29.2% | 4 qtrs — |
| 88 | MAN GROUP PLC | 114.8K +91.7K (+396.7%) | 5.15M +4.2M (+454.4%) | 0.14% +0.116 pp | 0.01% +0.007 pp | USD42.10 +6.5% | 3 qtrs — |
| 89 | SWISS NATIONAL BANK | 114.0K -12.4K (-9.8%) | 5.11M +34.5K (+0.7%) | 0.14% -0.016 pp | 0.00% +0.000 pp | USD25.50 +75.8% | 23 qtrs — |
| 90 | AMERIPRISE FINANCIAL INC | 109.5K +12.0K (+12.3%) | 4.91M +992.4K (+25.3%) | 0.14% +0.015 pp | 0.00% +0.000 pp | USD38.37 +16.8% | 6 qtrs — |
| 91 | PALO ALTO INVESTORS LP | 96.5K +96.5K (+100.0%) | 4.33M +4.3M (+100.0%) | 0.12% +0.122 pp | 0.60% +0.602 pp | USD44.82 +0.0% | 1 qtrs NEW |
| 92 | VERITION FUND MANAGEMENT LLC | 93.8K +36.6K (+64.1%) | 4.20M +1.9M (+83.2%) | 0.12% +0.046 pp | 0.02% +0.007 pp | USD41.97 +6.8% | 5 qtrs — |
| 93 | BNP PARIBAS ARBITRAGE, SNC | 93.5K -65.8K (-41.3%) | 4.19M -2.2M (-34.5%) | 0.12% -0.084 pp | 0.00% -0.002 pp | USD39.35 +13.9% | 22 qtrs — |
| 94 | GRANAHAN INVESTMENT MANAGEMENT, LLC | 92.8K +5.3K (+6.1%) | 4.16M +646.4K (+18.4%) | 0.12% +0.006 pp | 0.18% +0.034 pp | USD31.75 +41.2% | 28 qtrs — |
| 95 | ATIKA CAPITAL MANAGEMENT LLC | 92.5K +54.5K (+143.4%) | 4.15M +2.6M (+171.8%) | 0.12% +0.069 pp | 0.44% +0.314 pp | USD42.90 +4.5% | 12 qtrs — |
| 96 | RHUMBLINE ADVISERS | 90.1K -16.6K (-15.6%) | 4.04M -247.4K (-5.8%) | 0.11% -0.022 pp | 0.00% 0.000 pp | USD31.30 +43.2% | 8 qtrs — |
| 97 | ROYAL BANK OF CANADA | 89.8K -30.8K (-25.5%) | 4.02M -816.0K (-16.9%) | 0.11% -0.039 pp | 0.00% 0.000 pp | USD34.74 +29.0% | 13 qtrs — |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.79
Neutral
Ratio by volume
1.55
Bullish
Buys
22
Sells
28
Shares acquired
1.09M
Shares disposed
701.7K
Cash buys
—
Cash sales
17.00
Net activity
+388,293
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-13 | MORTIMER IAN | Director / Officer | S-Sale | D | Common Shares | 7,308 | 55.23 | 403.6K | 19,923 | D | ↗ |
| 2026-03-13 | KENNEY CHRISTOPHER JOHN | Officer | S-Sale | D | Common Shares | 1,410 | 55.23 | 77.9K | 7,069 | D | ↗ |
| 2026-03-13 | DiFabio Andrea | Officer | S-Sale | D | Common Shares | 1,342 | 55.23 | 74.1K | 7,301 | D | ↗ |
| 2026-03-12 | MORTIMER IAN | Director / Officer | M-Exempt | D | Restricted Share Units | 12,500 | 0.00 | — | 37,500 | D | ↗ |
| 2026-03-12 | KENNEY CHRISTOPHER JOHN | Officer | M-Exempt | D | Restricted Share Units | 3,750 | 0.00 | — | 11,250 | D | ↗ |
| 2026-03-12 | DiFabio Andrea | Officer | M-Exempt | D | Restricted Share Units | 3,750 | 0.00 | — | 11,250 | D | ↗ |
| 2026-03-10 | MORTIMER IAN | Director / Officer | S-Sale | D | Common Shares | 11,269 | 60.11 | 677.4K | 14,731 | D | ↗ |
| 2026-03-10 | KENNEY CHRISTOPHER JOHN | Officer | S-Sale | D | Common Shares | 2,771 | 60.11 | 166.6K | 4,729 | D | ↗ |
| 2026-03-10 | DiFabio Andrea | Officer | S-Sale | D | Common Shares | 2,607 | 60.11 | 156.7K | 4,893 | D | ↗ |
| 2026-03-09 | MORTIMER IAN | Director / Officer | M-Exempt | A | Common Shares | 20,000 | 0.00 | — | 26,000 | D | ↗ |
| 2026-03-09 | KENNEY CHRISTOPHER JOHN | Officer | M-Exempt | A | Common Shares | 7,500 | 0.00 | — | 7,500 | D | ↗ |
| 2026-03-09 | DiFabio Andrea | Officer | M-Exempt | A | Common Shares | 7,500 | 0.00 | — | 7,500 | D | ↗ |
| 2026-01-09 | MORTIMER IAN | Director / Officer | A-Award | A | Restricted Share Units | 65,000 | 0.00 | — | 65,000 | D | ↗ |
| 2026-01-09 | KENNEY CHRISTOPHER JOHN | Officer | A-Award | A | Restricted Share Units | 20,000 | 0.00 | — | 20,000 | D | ↗ |
| 2026-01-09 | DiFabio Andrea | Officer | A-Award | A | Restricted Share Units | 15,000 | 0.00 | — | 15,000 | D | ↗ |
| 2026-01-09 | Cline Darren S | Officer | A-Award | A | Restricted Share Units | 20,000 | 0.00 | — | 20,000 | D | ↗ |
| 2026-01-02 | MORTIMER IAN | Director / Officer | M-Exempt | A | Common Shares | 40,000 | 7.49 | 299.6K | 46,000 | D | ↗ |
| 2025-12-08 | MORTIMER IAN | Director / Officer | S-Sale | D | Common Shares | 2,010 | 46.32 | 93.1K | 6,000 | D | ↗ |
| 2025-12-05 | MORTIMER IAN | Director / Officer | S-Sale | D | Common Shares | 14,375 | 45.03 | 647.3K | 16,830 | D | ↗ |
| 2025-11-28 | MORTIMER IAN | Director / Officer | S-Sale | D | Common Shares | 97 | 45.01 | 4.4K | 31,205 | D | ↗ |
| 2025-10-15 | Kelly Thomas Patrick | Officer | A-Award | A | Share Option (Right to Buy) | 225,000 | 41.90 | 9.43M | 225,000 | D | ↗ |
| 2025-10-01 | MORTIMER IAN | Director / Officer | M-Exempt | A | Common Shares | 25,000 | 7.69 | 192.3K | 56,302 | D | ↗ |
| 2025-06-23 | Cline Darren S | Officer | — | — | No securities are beneficially owned. | 0 | 0.00 | — | 0 | D | ↗ |
| 2025-06-05 | Svoronos Dawn | Director | A-Award | A | Share Option (Right to Buy) | 17,012 | 30.73 | 522.8K | 17,012 | D | ↗ |
| 2025-06-05 | PATOU GARY | Director | A-Award | A | Share Option (Right to Buy) | 17,012 | 30.73 | 522.8K | 17,012 | D | ↗ |
| 2025-06-05 | Machado Patrick | Director | A-Award | A | Restricted Share Units | 2,645 | 0.00 | — | 2,645 | D | ↗ |
| 2025-06-05 | Gover Justin D. | Director | A-Award | A | Restricted Share Units | 2,645 | 0.00 | — | 2,645 | D | ↗ |
| 2025-06-05 | GAROFALO ELIZABETH A. | Director | A-Award | A | Restricted Share Units | 2,645 | 0.00 | — | 2,645 | D | ↗ |
| 2025-06-05 | GANNON STEVEN | Director | A-Award | A | Restricted Share Units | 2,645 | 0.00 | — | 2,645 | D | ↗ |
| 2025-06-05 | Cannon Gillian | Director | A-Award | A | Restricted Share Units | 2,645 | 0.00 | — | 2,645 | D | ↗ |
| 2025-05-14 | GANNON STEVEN | Director | M-Exempt | A | Common Shares | 5,144 | 12.57 | 64.7K | 7,144 | D | ↗ |
| 2025-03-12 | MORTIMER IAN | Director / Officer | A-Award | A | Share Option (Right to Buy) | 275,000 | 35.48 | 9.76M | 275,000 | D | ↗ |
| 2025-03-12 | KENNEY CHRISTOPHER JOHN | Officer | A-Award | A | Share Option (Right to Buy) | 80,000 | 35.48 | 2.84M | 80,000 | D | ↗ |
| 2025-03-12 | DiFabio Andrea | Officer | A-Award | A | Share Option (Right to Buy) | 80,000 | 35.48 | 2.84M | 80,000 | D | ↗ |
| 2025-01-27 | MORTIMER IAN | Director / Officer | M-Exempt | A | Common Shares | 15,166 | 17.76 | 269.3K | 46,468 | D | ↗ |
| 2025-01-24 | MORTIMER IAN | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 22,468 | 17.76 | 399.0K | 16,315 | D | ↗ |
| 2025-01-23 | MORTIMER IAN | Director / Officer | S-Sale | D | Common Shares | 16,217 | 40.08 | 650.0K | 31,302 | D | ↗ |
| 2024-12-18 | AULIN SHERRY | Officer | S-Sale | D | Common Shares | 7,199 | 41.23 | 296.8K | 0 | D | ↗ |
| 2024-11-22 | PATOU GARY | Director | S-Sale | D | Common Shares | 2,040 | 41.05 | 83.7K | 23,573 | D | ↗ |
| 2024-06-05 | Svoronos Dawn | Director | A-Award | A | Stock Option (Right to Buy) | 15,542 | 38.16 | 593.1K | 15,542 | — | ↗ |
| 2024-06-05 | PATOU GARY | Director | A-Award | A | Stock Option (Right to Buy) | 15,542 | 38.16 | 593.1K | 15,542 | — | ↗ |
| 2024-06-05 | Machado Patrick | Director | A-Award | A | Stock Option (Right to Buy) | 15,542 | 38.16 | 593.1K | 15,542 | — | ↗ |
| 2024-06-05 | Gover Justin D. | Director | A-Award | A | Stock Option (Right to Buy) | 15,542 | 38.16 | 593.1K | 15,542 | — | ↗ |
| 2024-06-05 | GAROFALO ELIZABETH A. | Director | A-Award | A | Stock Option (Right to Buy) | 15,542 | 38.16 | 593.1K | 15,542 | — | ↗ |
| 2024-06-05 | GANNON STEVEN | Director | A-Award | A | Stock Option (Right to Buy) | 15,542 | 38.16 | 593.1K | 15,542 | — | ↗ |
| 2024-06-05 | Cannon Gillian | Director | A-Award | A | Stock Option (Right to Buy) | 15,542 | 38.16 | 593.1K | 15,542 | — | ↗ |
| 2024-03-11 | Von Seggern Christopher | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 44.37 | 4.44M | 100,000 | — | ↗ |
| 2024-03-11 | ROBIN SHERRINGTON | Officer | A-Award | A | Stock Option (Right to Buy) | 65,000 | 44.37 | 2.88M | 65,000 | — | ↗ |
| 2024-03-11 | MORTIMER IAN | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 250,000 | 44.37 | 11.09M | 250,000 | — | ↗ |
| 2024-03-11 | KENNEY CHRISTOPHER JOHN | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 44.37 | 4.44M | 100,000 | — | ↗ |
| 2024-03-11 | EMPFIELD JAMES R. | Officer | A-Award | A | Stock Option (Right to Buy) | 65,000 | 44.37 | 2.88M | 65,000 | — | ↗ |
| 2024-03-11 | DiFabio Andrea | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 44.37 | 4.44M | 100,000 | — | ↗ |
| 2024-03-11 | AULIN SHERRY | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 44.37 | 4.44M | 100,000 | — | ↗ |
| 2024-03-08 | GAROFALO ELIZABETH A. | Director | M-Exempt | D | Stock Option (Right to Buy) | 3,500 | 18.56 | 65.0K | 16,500 | — | ↗ |
| 2024-03-07 | ROBIN SHERRINGTON | Officer | F-InKind | D | Common Shares | 215 | 45.96 | 9.9K | 9,417 | — | ↗ |
| 2024-03-07 | GANNON STEVEN | Director | S-Sale | D | Common Shares | 2,000 | 46.20 | 92.4K | 2,000 | — | ↗ |
| 2023-12-29 | ROBIN SHERRINGTON | Officer | J-Other | D | Common Shares | 8,398 | 0.00 | — | 8,398 | — | ↗ |
| 2023-12-19 | AZAB MOHAMMAD | Director | M-Exempt | A | Common Shares | 3,497 | 9.85 | 34.4K | 74,225 | — | ↗ |
| 2023-12-14 | PATOU GARY | Director | S-Sale | D | Common Shares | 7,598 | 41.05 | 311.9K | 4,902 | — | ↗ |
| 2023-12-13 | PATOU GARY | Director | M-Exempt | D | Stock Option (Right to Buy) | 2,800 | 9.85 | 27.6K | 0 | — | ↗ |
| 2023-08-24 | Svoronos Dawn | Director | S-Sale | D | Common Shares | 25,000 | 38.70 | 967.5K | 25,000 | — | ↗ |
| 2023-08-10 | Gover Justin D. | Director | A-Award | A | Stock Option (Right to Buy) | 28,000 | 38.39 | 1.07M | 28,000 | — | ↗ |
| 2023-08-10 | Cannon Gillian | Director | A-Award | A | Stock Option (Right to Buy) | 28,000 | 38.39 | 1.07M | 28,000 | — | ↗ |
| 2023-08-08 | Gover Justin D. | Director | — | D | No securities are beneficially owned. | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-08-08 | Cannon Gillian | Director | — | D | No securities are beneficially owned. | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-06-02 | Svoronos Dawn | Director | A-Award | A | Stock Option (Right to Buy) | 18,475 | 38.96 | 719.8K | 18,475 | — | ↗ |
| 2023-06-02 | PIMSTONE SIMON N. | Director | A-Award | A | Stock Option (Right to Buy) | 18,475 | 38.96 | 719.8K | 18,475 | — | ↗ |
| 2023-06-02 | PATOU GARY | Director | A-Award | A | Stock Option (Right to Buy) | 18,475 | 38.96 | 719.8K | 18,475 | — | ↗ |
| 2023-06-02 | Machado Patrick | Director | A-Award | A | Stock Option (Right to Buy) | 18,475 | 38.96 | 719.8K | 18,475 | — | ↗ |
| 2023-06-02 | GAROFALO ELIZABETH A. | Director | A-Award | A | Stock Option (Right to Buy) | 18,475 | 38.96 | 719.8K | 18,475 | — | ↗ |
| 2023-06-02 | GANNON STEVEN | Director | A-Award | A | Stock Option (Right to Buy) | 18,475 | 38.96 | 719.8K | 18,475 | — | ↗ |
| 2023-06-02 | AZAB MOHAMMAD | Director | A-Award | A | Stock Option (Right to Buy) | 18,475 | 38.96 | 719.8K | 18,475 | — | ↗ |
| 2023-06-01 | PIMSTONE SIMON N. | Director | M-Exempt | A | Common Shares | 9,318 | 7.69 | 71.7K | 15,318 | — | ↗ |
| 2023-05-31 | PIMSTONE SIMON N. | Director | F-InKind | D | Common Shares | 23,144 | 38.37 | 888.0K | 32,856 | — | ↗ |
| 2023-05-30 | PIMSTONE SIMON N. | Director | S-Sale | D | Common Shares | 18,006 | 38.63 | 695.6K | 37,000 | — | ↗ |
| 2023-05-24 | MORTIMER IAN | Director / Officer | F-InKind | D | Common Shares | 1,171 | 41.84 | 49.0K | 32,709 | — | ↗ |
| 2023-03-24 | KENNEY CHRISTOPHER JOHN | Officer | S-Sale | D | Common Shares | 700 | 35.01 | 24.5K | 0 | — | ↗ |
| 2023-03-10 | Von Seggern Christopher | Officer | A-Award | A | Stock Option (Right to Buy) | 90,000 | 34.18 | 3.08M | 90,000 | — | ↗ |
| 2023-03-10 | ROBIN SHERRINGTON | Officer | A-Award | A | Stock Option (Right to Buy) | 75,000 | 34.18 | 2.56M | 75,000 | — | ↗ |
| 2023-03-10 | MORTIMER IAN | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 380,000 | 34.18 | 12.99M | 380,000 | — | ↗ |
| 2023-03-10 | KENNEY CHRISTOPHER JOHN | Officer | A-Award | A | Stock Option (Right to Buy) | 120,000 | 34.18 | 4.10M | 120,000 | — | ↗ |
| 2023-03-10 | EMPFIELD JAMES R. | Officer | A-Award | A | Stock Option (Right to Buy) | 75,000 | 34.18 | 2.56M | 75,000 | — | ↗ |
| 2023-03-10 | DiFabio Andrea | Officer | A-Award | A | Stock Option (Right to Buy) | 45,000 | 34.18 | 1.54M | 45,000 | — | ↗ |
| 2023-03-10 | AULIN SHERRY | Officer | A-Award | A | Stock Option (Right to Buy) | 120,000 | 34.18 | 4.10M | 120,000 | — | ↗ |
| 2023-03-07 | PIMSTONE SIMON N. | Director | F-InKind | D | Common Shares | 2,160 | 37.13 | 80.2K | 44,992 | — | ↗ |
| 2022-12-12 | AZAB MOHAMMAD | Director | M-Exempt | A | Common Shares | 3,086 | 2.68 | 8.3K | 69,905 | — | ↗ |
| 2022-11-25 | PATOU GARY | Director | M-Exempt | A | Common Shares | 2,057 | 2.68 | 5.5K | 25,630 | — | ↗ |
| 2022-11-07 | DiFabio Andrea | Officer | A-Award | A | Stock Option (Right to Buy) | 135,000 | 0.00 | — | 135,000 | — | ↗ |
| 2022-09-02 | AULIN SHERRY | Officer | S-Sale | D | Common Shares | 15,355 | 39.57 | 607.6K | 0 | — | ↗ |
| 2022-09-01 | ROBIN SHERRINGTON | Officer | S-Sale | D | Common Shares | 35,103 | 38.03 | 1.33M | 25,572 | — | ↗ |
| 2022-08-31 | ROBIN SHERRINGTON | Officer | M-Exempt | A | Common Shares | 50,000 | 4.75 | 237.5K | 66,796 | — | ↗ |
| 2022-08-12 | PIMSTONE SIMON N. | Director | S-Sale | D | Common Shares | 32,058 | 38.29 | 1.23M | 26,000 | — | ↗ |
| 2022-08-12 | EMPFIELD JAMES R. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 45,000 | 0.00 | — | 0 | — | ↗ |
| 2022-06-28 | Svoronos Dawn | Director | A-Award | A | Stock Option (Right to Buy) | 18,000 | 0.00 | — | 18,000 | — | ↗ |
| 2022-06-28 | PIMSTONE SIMON N. | Director | A-Award | A | Stock Option (Right to Buy) | 18,000 | 0.00 | — | 18,000 | — | ↗ |
| 2022-06-28 | PATOU GARY | Director | A-Award | A | Stock Option (Right to Buy) | 18,000 | 0.00 | — | 18,000 | — | ↗ |
| 2022-06-28 | Machado Patrick | Director | A-Award | A | Stock Option (Right to Buy) | 18,000 | 0.00 | — | 18,000 | — | ↗ |
| 2022-06-28 | GAROFALO ELIZABETH A. | Director | A-Award | A | Stock Option (Right to Buy) | 18,000 | 30.11 | 542.0K | 18,000 | — | ↗ |
| 2022-06-28 | GANNON STEVEN | Director | A-Award | A | Stock Option (Right to Buy) | 18,000 | 0.00 | — | 18,000 | — | ↗ |
| 2022-06-28 | AZAB MOHAMMAD | Director | A-Award | A | Stock Option (Right to Buy) | 18,000 | 30.11 | 542.0K | 18,000 | — | ↗ |
| 2022-03-10 | Von Seggern Christopher | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2022-03-10 | ROBIN SHERRINGTON | Officer | A-Award | A | Stock Option (Right to Buy) | 75,000 | 0.00 | — | 75,000 | — | ↗ |
| 2022-03-10 | PIMSTONE SIMON N. | Officer | A-Award | A | Stock Option (Right to Buy) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-03-10 | MORTIMER IAN | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 400,000 | 30.01 | 12.00M | 400,000 | — | ↗ |
| 2022-03-10 | KENNEY CHRISTOPHER JOHN | Officer | A-Award | A | Stock Option (Right to Buy) | 125,000 | 0.00 | — | 125,000 | — | ↗ |
| 2022-03-10 | EMPFIELD JAMES R. | Officer | A-Award | A | Stock Option (Right to Buy) | 65,000 | 0.00 | — | 65,000 | — | ↗ |
| 2022-03-10 | AULIN SHERRY | Officer | A-Award | A | Stock Option (Right to Buy) | 125,000 | 0.00 | — | 125,000 | — | ↗ |
| 2022-03-08 | PIMSTONE SIMON N. | Director | S-Sale | D | Common Shares | 2,500 | 30.80 | 77.0K | 193,135 | — | ↗ |
| 2022-03-07 | EMPFIELD JAMES R. | Officer | S-Sale | D | Common Shares | 31,048 | 30.54 | 948.2K | 10,000 | — | ↗ |
| 2022-03-04 | ROBIN SHERRINGTON | Officer | M-Exempt | D | Stock Option (Right to Buy) | 6,172 | 3.67 | 22.7K | 0 | — | ↗ |
| 2022-03-04 | PIMSTONE SIMON N. | Director | F-InKind | D | Common Shares | 1,990 | 30.23 | 60.2K | 228,772 | — | ↗ |
| 2022-03-04 | EMPFIELD JAMES R. | Officer | S-Sale | D | Common Shares | 18,315 | 30.79 | 563.9K | 10,000 | — | ↗ |
| 2022-01-21 | KENNEY CHRISTOPHER JOHN | Officer | P-Purchase | A | Common Shares | 700 | 28.81 | 20.2K | 700 | — | ↗ |
| 2021-12-15 | AZAB MOHAMMAD | Director | M-Exempt | A | Common Shares | 3,086 | 3.67 | 11.3K | 66,819 | — | ↗ |
| 2021-12-08 | PATOU GARY | Director | M-Exempt | A | Common Shares | 2,057 | 3.67 | 7.5K | 25,630 | — | ↗ |
| 2021-12-06 | Von Seggern Christopher | Officer | P-Purchase | A | Common Shares | 4,000 | 24.40 | 97.6K | 4,000 | — | ↗ |
| 2021-11-15 | PIMSTONE SIMON N. | Director | S-Sale | D | Common Shares | 17,557 | 31.33 | 550.1K | 210,186 | — | ↗ |
| 2021-08-23 | KENNEY CHRISTOPHER JOHN | Officer | — | D | No securities are beneficially owned. | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-06-03 | Svoronos Dawn | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 18.56 | 185.6K | 10,000 | — | ↗ |
| 2021-06-03 | PATOU GARY | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 18.56 | 185.6K | 10,000 | — | ↗ |
| 2021-06-03 | Machado Patrick | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 18.56 | 185.6K | 10,000 | — | ↗ |
| 2021-06-03 | MORTIMER IAN | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 125,000 | 18.56 | 2.32M | 125,000 | — | ↗ |
| 2021-06-03 | Hayden Michael R | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 18.56 | 185.6K | 10,000 | — | ↗ |
| 2021-06-03 | GAROFALO ELIZABETH A. | Director | — | D | No securities are beneficially owned. | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-06-03 | GANNON STEVEN | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 18.56 | 185.6K | 10,000 | — | ↗ |
| 2021-06-03 | AZAB MOHAMMAD | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 18.56 | 185.6K | 10,000 | — | ↗ |
| 2021-06-03 | AULIN SHERRY | Officer | — | D | Stock Option (Right to Buy) | 22,000 | 11.58 | 254.8K | 0 | — | ↗ |
| 2021-05-28 | ROBIN SHERRINGTON | Officer | F-InKind | D | Common Shares | 2,024 | 18.91 | 38.3K | 27,117 | — | ↗ |
| 2021-05-27 | HOLLER FRANK A | Director | M-Exempt | A | Common Shares | 36,008 | 3.76 | 135.4K | 160,628 | — | ↗ |
| 2021-05-24 | PIMSTONE SIMON N. | Director / Officer | M-Exempt | A | Common Shares | 22,633 | 3.76 | 85.1K | 232,819 | — | ↗ |
| 2021-05-18 | TARNOW MICHAEL M | Director | M-Exempt | D | Stock Option (Right to Buy) | 2,057 | 3.87 | 8.0K | 0 | — | ↗ |
| 2021-05-18 | Hayden Michael R | Director | M-Exempt | D | Stock Option (Right to Buy) | 3,500 | 3.85 | 13.5K | 0 | — | ↗ |
| 2021-03-17 | PATOU GARY | Director | L-Small | A | Common Shares | 100 | 19.49 | 1.9K | 100 | — | ↗ |
| 2021-03-12 | Von Seggern Christopher | Officer | A-Award | A | Stock Option (Right to Buy) | 60,000 | 20.55 | 1.23M | 60,000 | — | ↗ |
| 2021-03-12 | ROBIN SHERRINGTON | Officer | A-Award | A | Stock Option (Right to Buy) | 65,000 | 20.55 | 1.34M | 65,000 | — | ↗ |
| 2021-03-12 | PIMSTONE SIMON N. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 225,000 | 20.55 | 4.62M | 225,000 | — | ↗ |
| 2021-03-12 | MORTIMER IAN | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 20.55 | 2.06M | 100,000 | — | ↗ |
| 2021-03-12 | EMPFIELD JAMES R. | Officer | A-Award | A | Stock Option (Right to Buy) | 65,000 | 20.55 | 1.34M | 65,000 | — | ↗ |
| 2021-02-18 | Hayden Michael R | Director | M-Exempt | A | Common Shares | 30,864 | 2.68 | 82.7K | 92,076 | — | ↗ |
| 2021-02-16 | Hayden Michael R | Director | M-Exempt | A | Common Shares | 5,144 | 2.68 | 13.8K | 112,706 | — | ↗ |
| 2020-12-15 | AZAB MOHAMMAD | Director | M-Exempt | A | Common Shares | 3,086 | 3.76 | 11.6K | 63,733 | — | ↗ |
| 2020-11-05 | Machado Patrick | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 11.85 | 237.0K | 20,000 | — | ↗ |
| 2020-10-28 | TARNOW MICHAEL M | Director | M-Exempt | A | Common Shares | 5,144 | 3.76 | 19.3K | 80,001 | — | ↗ |
| 2020-10-28 | PATOU GARY | Director | M-Exempt | A | Common Shares | 2,057 | 3.76 | 7.7K | 23,573 | — | ↗ |
| 2020-08-20 | PIMSTONE SIMON N. | Director / Officer | J-Other | D | Common Shares | 45,000 | 0.00 | — | 210,186 | — | ↗ |
| 2020-08-17 | Von Seggern Christopher | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 11.27 | 1.13M | 100,000 | — | ↗ |
| 2020-06-09 | TARNOW MICHAEL M | Director | M-Exempt | A | Common Shares | 5,144 | 3.52 | 18.1K | 69,713 | — | ↗ |
| 2020-06-01 | TARNOW MICHAEL M | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 13.11 | 131.1K | 10,000 | — | ↗ |
| 2020-06-01 | Svoronos Dawn | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 13.11 | 131.1K | 10,000 | — | ↗ |
| 2020-06-01 | ROBIN SHERRINGTON | Officer | F-InKind | D | Common Shares | 1,630 | 13.70 | 22.3K | 16,796 | — | ↗ |
| 2020-06-01 | PIMSTONE SIMON N. | Director / Officer | S-Sale | D | Common Shares | 3,000 | 14.43 | 43.3K | 255,186 | — | ↗ |
| 2020-06-01 | PATOU GARY | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 13.11 | 131.1K | 10,000 | — | ↗ |
| 2020-06-01 | Hayden Michael R | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 13.11 | 131.1K | 10,000 | — | ↗ |
| 2020-06-01 | HOLLER FRANK A | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 13.11 | 131.1K | 10,000 | — | ↗ |
| 2020-06-01 | GANNON STEVEN | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 13.11 | 131.1K | 10,000 | — | ↗ |
| 2020-06-01 | Desjardins Clarissa | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 13.11 | 131.1K | 10,000 | — | ↗ |
| 2020-06-01 | AZAB MOHAMMAD | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 13.11 | 131.1K | 10,000 | — | ↗ |
| 2020-05-29 | PIMSTONE SIMON N. | Director / Officer | S-Sale | D | Common Shares | 5,000 | 13.99 | 70.0K | 258,186 | — | ↗ |
| 2020-05-29 | HOLLER FRANK A | Director | M-Exempt | A | Common Shares | 3,086 | 3.56 | 11.0K | 122,041 | — | ↗ |
| 2020-05-26 | PIMSTONE SIMON N. | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 6,172 | 3.56 | 22.0K | 0 | — | ↗ |
| 2020-03-12 | ROBIN SHERRINGTON | Officer | A-Award | A | Stock Option (Right to Buy) | 65,000 | 11.58 | 752.7K | 65,000 | — | ↗ |
| 2020-03-12 | PIMSTONE SIMON N. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 280,000 | 11.58 | 3.24M | 280,000 | — | ↗ |
| 2020-03-12 | MORTIMER IAN | Officer | A-Award | A | Stock Option (Right to Buy) | 145,000 | 11.58 | 1.68M | 145,000 | — | ↗ |
| 2020-03-12 | EMPFIELD JAMES R. | Officer | A-Award | A | Stock Option (Right to Buy) | 65,000 | 11.58 | 752.7K | 65,000 | — | ↗ |
| 2020-03-12 | AYCARDI-FONSECA ERNESTO | Officer | A-Award | A | Stock Option (Right to Buy) | 65,000 | 11.58 | 752.7K | 65,000 | — | ↗ |
| 2020-01-13 | Desjardins Clarissa | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 16.42 | 410.5K | 25,000 | — | ↗ |
| 2019-12-16 | AZAB MOHAMMAD | Director | M-Exempt | A | Common Shares | 3,086 | 3.56 | 11.0K | 60,647 | — | ↗ |
| 2019-12-04 | PATOU GARY | Director | M-Exempt | D | Stock Option (Right to Buy) | 2,057 | 3.56 | 7.3K | 0 | — | ↗ |
| 2019-11-21 | TARNOW MICHAEL M | Director | M-Exempt | A | Common Shares | 5,144 | 3.56 | 18.3K | 69,713 | — | ↗ |
| 2019-09-20 | PIMSTONE SIMON N. | Director / Officer | S-Sale | D | Common Shares | 10,395 | 9.51 | 98.9K | 258,122 | — | ↗ |
| 2019-09-20 | HOLLER FRANK A | Director | S-Sale | D | Common Shares | 5,206 | 9.39 | 48.9K | 118,955 | — | ↗ |
| 2019-09-19 | HOLLER FRANK A | Director | S-Sale | D | Common Shares | 7,600 | 9.27 | 70.5K | 124,161 | — | ↗ |
| 2019-09-18 | HOLLER FRANK A | Director | S-Sale | D | Common Shares | 4,368 | 9.28 | 40.5K | 131,761 | — | ↗ |
| 2019-09-17 | PIMSTONE SIMON N. | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 9,259 | 3.07 | 28.4K | 0 | — | ↗ |
| 2019-09-17 | HOLLER FRANK A | Director | S-Sale | D | Common Shares | 5,069 | 9.32 | 47.2K | 136,129 | — | ↗ |
| 2019-09-16 | TARNOW MICHAEL M | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 9.44 | 141.6K | 15,000 | — | ↗ |
| 2019-09-16 | Svoronos Dawn | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 9.44 | 141.6K | 15,000 | — | ↗ |
| 2019-09-16 | SCHELLER RICHARD H | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 9.44 | 141.6K | 15,000 | — | ↗ |
| 2019-09-16 | ROBIN SHERRINGTON | Officer | A-Award | A | Stock Option (Right to Buy) | 45,000 | 9.44 | 424.8K | 45,000 | — | ↗ |
| 2019-09-16 | PIMSTONE SIMON N. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 280,000 | 9.44 | 2.64M | 280,000 | — | ↗ |
| 2019-09-16 | PATOU GARY | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 9.44 | 141.6K | 15,000 | — | ↗ |
| 2019-09-16 | MORTIMER IAN | Officer | A-Award | A | Stock Option (Right to Buy) | 135,000 | 9.44 | 1.27M | 135,000 | — | ↗ |
| 2019-09-16 | Hayden Michael R | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 9.44 | 141.6K | 15,000 | — | ↗ |
| 2019-09-16 | HOLLER FRANK A | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 9.44 | 141.6K | 15,000 | — | ↗ |
| 2019-09-16 | GANNON STEVEN | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 9.44 | 141.6K | 15,000 | — | ↗ |
| 2019-09-16 | EMPFIELD JAMES R. | Officer | A-Award | A | Stock Option (Right to Buy) | 40,000 | 9.44 | 377.6K | 40,000 | — | ↗ |
| 2019-09-16 | AZAB MOHAMMAD | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 9.44 | 141.6K | 15,000 | — | ↗ |
| 2019-09-16 | AYCARDI-FONSECA ERNESTO | Officer | A-Award | A | Stock Option (Right to Buy) | 65,000 | 9.44 | 613.6K | 65,000 | — | ↗ |
| 2019-09-13 | AZAB MOHAMMAD | Director | S-Sale | D | Common Shares | 23 | 9.31 | 214.18 | 57,561 | — | ↗ |
| 2019-09-12 | ROBIN SHERRINGTON | Officer | M-Exempt | D | Stock Option (Right to Buy) | 6,172 | 3.07 | 18.9K | 0 | — | ↗ |
| 2019-09-12 | HOLLER FRANK A | Director | M-Exempt | D | Stock Option (Right to Buy) | 3,086 | 3.70 | 11.4K | 0 | — | ↗ |
| 2019-05-21 | TARNOW MICHAEL M | Director | M-Exempt | A | Common Shares | 2,057 | 3.21 | 6.6K | 64,569 | — | ↗ |
| 2019-03-19 | Hayden Michael R | Director | M-Exempt | A | Common Shares | 20,576 | 3.38 | 69.5K | 50,924 | — | ↗ |
| 2019-03-11 | Hayden Michael R | Director | G-Gift | A | Common Shares | 17,337 | 0.00 | — | 114,403 | — | ↗ |
| 2018-12-21 | TARNOW MICHAEL M | Director | G-Gift | D | Common Shares | 5,000 | 0.00 | — | 62,512 | — | ↗ |
| 2018-12-14 | PATOU GARY | Director | M-Exempt | A | Common Shares | 2,057 | 3.07 | 6.3K | 19,459 | — | ↗ |
| 2018-12-11 | COHEN CHARLES J. | Officer | F-InKind | D | Common Shares | 1,644 | 7.00 | 11.5K | 6,550 | — | ↗ |
| 2018-12-06 | AZAB MOHAMMAD | Director | M-Exempt | A | Common Shares | 3,086 | 3.07 | 9.5K | 57,584 | — | ↗ |
| 2018-06-21 | TARNOW MICHAEL M | Director | M-Exempt | A | Common Shares | 5,144 | 3.07 | 15.8K | 67,512 | — | ↗ |
| 2018-06-21 | AZAB MOHAMMAD | Director | M-Exempt | A | Common Shares | 10,288 | 3.70 | 38.1K | 54,498 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-10.9K
Shares Outstanding
78.95M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Ian Mortimer President and Chief Executive Officer | 786.0K | — | 1.77M | 6.07M | 550.2K | 46.3K | 9.22M | 85.01% | ↗ |
| 2 | 2025 | Thomas Kelly | 114.5K | — | 1.26M | 5.81M | 51.5K | 6.0K | 7.24M | 97.62% | ↗ |
| 3 | 2025 | Darren Cline | 279.7K | — | — | 3.63M | 125.8K | 14.6K | 4.05M | 89.62% | ↗ |
| 4 | 2025 | Christopher Kenney Chief Medical Officer | 565.0K | — | 532.2K | 1.76M | 254.3K | 29.4K | 3.15M | 73.02% | ↗ |
| 5 | 2025 | Andrea DiFabio Chief Legal Officer and Corporate Secretary | 510.0K | — | 532.2K | 1.76M | 229.5K | 26.7K | 3.06M | 74.99% | ↗ |
| 6 | 2025 | Sherry Aulin Former Chief Financial Officer | 330.4K | 1.5K | — | — | — | 24.5K | 356.5K | 0.00% | ↗ |
| 7 | 2024 | Ian Mortimer President and Chief Executive Officer | 714.6K | — | 887.4K | 7.72M | 425.4K | 44.3K | 9.80M | 87.91% | ↗ |
| 8 | 2024 | Ian Mortimer President and Chief Executive Officer | 714.6K | — | 887.4K | 7.72M | 425.4K | 44.3K | 9.80M | 87.91% | ↗ |
| 9 | 2024 | Christopher Kenney Chief Medical Officer | 540.0K | — | 332.8K | 3.09M | 206.6K | 28.2K | 4.20M | 81.54% | ↗ |
| 10 | 2024 | Christopher Kenney Chief Medical Officer | 540.0K | — | 332.8K | 3.09M | 206.6K | 28.2K | 4.20M | 81.54% | ↗ |
| 11 | 2024 | Sherry Aulin Chief Financial Officer | 509.7K | — | 332.8K | 3.09M | 195.1K | 37.9K | 4.16M | 82.17% | ↗ |
| 12 | 2024 | Sherry Aulin Former Chief Financial Officer | 509.7K | — | 332.8K | 3.09M | 195.1K | 37.9K | 4.16M | 82.17% | ↗ |
| 13 | 2024 | Andrea DiFabio Chief Legal Officer and Corporate Secretary | 490.0K | — | 332.8K | 3.09M | 166.6K | 25.7K | 4.10M | 83.38% | ↗ |
| 14 | 2024 | Andrea DiFabio Chief Legal Officer and Corporate Secretary | 490.0K | — | 332.8K | 3.09M | 166.6K | 25.7K | 4.10M | 83.38% | ↗ |
| 15 | 2024 | Christopher Von Seggern Chief Commercial Officer | 480.0K | — | 332.8K | 3.09M | 163.2K | 25.2K | 4.09M | 83.66% | ↗ |
| 16 | 2023 | Ian Mortimer President and Chief Executive Officer | 666.0K | 1.6K | — | 9.05M | 359.7K | 39.5K | 10.12M | 89.46% | ↗ |
| 17 | 2023 | Christopher Kenney Chief Medical Officer | 510.0K | — | — | 2.86M | 183.6K | 26.2K | 3.58M | 79.88% | ↗ |
| 18 | 2023 | Sherry Aulin Chief Financial Officer | 465.7K | — | — | 2.86M | 167.6K | 31.5K | 3.52M | 81.13% | ↗ |
| 19 | 2023 | Christopher Von Seggern Chief Commercial Officer | 440.0K | — | — | 2.14M | 158.4K | 22.7K | 2.76M | 77.53% | ↗ |
| 20 | 2023 | Robin Sherrington Executive Vice President, Strategy and Innovation | 410.6K | — | — | 1.79M | 147.8K | 28.7K | 2.37M | 75.27% | ↗ |
| 21 | 2023 | Andrea DiFabio Chief Legal Officer and Corporate Secretary | 460.0K | — | — | 1.07M | 165.6K | 23.7K | 1.72M | 62.27% | ↗ |
| 22 | 2022 | Ian Mortimer President and Chief Executive Officer | 594.7K | — | — | 8.25M | 343.4K | 35.7K | 9.23M | 89.45% | ↗ |
| 23 | 2022 | Andrea DiFabio Chief Legal Officer and Corporate Secretary | 68.4K | 100.0K | — | 3.35M | 28.7K | 3.4K | 3.55M | 94.36% | ↗ |
| 24 | 2022 | Christopher Kenney Chief Medical Officer | 465.0K | — | — | 2.58M | 195.3K | 23.9K | 3.26M | 79.04% | ↗ |
| 25 | 2022 | Sherry Aulin Chief Financial Officer | 425.3K | — | — | 2.58M | 178.6K | 29.3K | 3.21M | 80.29% | ↗ |
| 26 | 2022 | Christopher Von Seggern Chief Commercial Officer | 420.0K | — | — | 2.06M | 176.4K | 21.7K | 2.68M | 76.95% | ↗ |
| 27 | 2021 | Simon Pimstone Executive Chair of the Board | 525.5K | — | — | 3.10M | 450.4K | 35.6K | 4.12M | 75.43% | ↗ |
| 28 | 2021 | Ian Mortimer President and Chief Executive Officer | 524.3K | — | — | 2.94M | 400.5K | 32.4K | 3.89M | 75.43% | ↗ |
| 29 | 2021 | Sherry Aulin Chief Financial Officer | 282.7K | — | — | 1.55M | 154.8K | 21.1K | 2.01M | 77.17% | ↗ |
| 30 | 2021 | Christopher Kenney Chief Medical Officer | 162.1K | — | — | 1.67M | 97.3K | 8.5K | 1.94M | 86.16% | ↗ |
| 31 | 2020 | Simon Pimstone Executive Chair of the Board | 498.1K | 2.1K | — | 2.15M | 254.0K | 33.5K | 2.94M | 73.22% | ↗ |
| 32 | 2020 | Simon N. Pimstone Chief Executive Officer | 498.1K | 2.1K | — | 2.15M | 254.0K | 33.5K | 2.94M | 73.22% | ↗ |
| 33 | 2020 | Ian Mortimer President and Chief Executive Officer | 462.0K | — | — | 1.12M | 176.7K | 28.9K | 1.78M | 62.56% | ↗ |
| 34 | 2020 | Ian C. Mortimer President and Chief Financial Officer | 462.0K | — | — | 1.12M | 176.7K | 28.9K | 1.78M | 62.56% | ↗ |
| 35 | 2020 | Ernesto Aycardi Chief Medical Officer | 434.7K | — | — | 500.1K | 147.8K | 24.2K | 1.11M | 45.18% | ↗ |
| 36 | 2019 | Simon Pimstone Executive Chair of the Board | 445.7K | — | — | 1.80M | 334.3K | 31.3K | 2.61M | 68.95% | ↗ |
| 37 | 2019 | Simon N. Pimstone Chief Executive Officer | 445.7K | — | — | 1.80M | 334.3K | 31.3K | 2.61M | 68.95% | ↗ |
| 38 | 2019 | Ian C. Mortimer President and Chief Financial Officer | 420.9K | — | — | 868.6K | 236.7K | 27.2K | 1.55M | 55.91% | ↗ |
| 39 | 2019 | Ian C. Mortimer President and Chief Financial Officer, Corporate Secretary | 420.9K | — | — | 868.6K | 236.7K | 27.2K | 1.55M | 55.91% | ↗ |
| 40 | 2019 | Ian Mortimer President and Chief Executive Officer | 420.9K | — | — | 868.6K | 236.7K | 27.2K | 1.55M | 55.91% | ↗ |
| 41 | 2019 | Ernesto Aycardi Chief Medical Officer | 420.0K | — | — | 418.2K | 210.0K | 24.8K | 1.07M | 38.97% | ↗ |
| 42 | 2018 | Simon N. Pimstone Chief Executive Officer | 400.6K | — | — | 485.5K | 250.3K | 28.8K | 1.17M | 41.66% | ↗ |
| 43 | 2018 | Ian C. Mortimer President, Chief Financial Officer and Corporate Secretary | 342.5K | — | — | 364.1K | 192.7K | 23.4K | 922.7K | 39.46% | ↗ |
| 44 | 2018 | Ian C. Mortimer President and Chief Financial Officer, Corporate Secretary | 342.5K | — | — | 364.1K | 192.7K | 23.4K | 922.7K | 39.46% | ↗ |
| 45 | 2018 | Ian C. Mortimer President and Chief Financial Officer | 342.5K | — | — | 364.1K | 192.7K | 23.4K | 922.7K | 39.46% | ↗ |
| 46 | 2018 | Ernesto Aycardi Chief Medical Officer | 316.7K | 30.0K | — | 169.7K | 158.3K | 17.3K | 692.0K | 24.52% | ↗ |
| 47 | 2017 | Simon N. Pimstone Chief Executive Officer | 399.1K | — | — | 922.2K | 119.7K | 28.2K | 1.47M | 62.77% | ↗ |
| 48 | 2017 | Ian C. Mortimer President and Chief Financial Officer, Corporate Secretary | 311.5K | — | — | 537.3K | 74.8K | 21.1K | 944.8K | 56.87% | ↗ |
| 49 | 2017 | Ian C. Mortimer President, Chief Financial Officer and Corporate Secretary | 311.5K | — | — | 537.3K | 74.8K | 21.1K | 944.8K | 56.87% | ↗ |
| 50 | 2017 | Y. Paul Goldberg Senior Vice President, Clinical Development | 278.4K | — | — | 201.2K | 58.5K | 20.7K | 558.7K | 36.01% | ↗ |
| 51 | 2017 | Robin P. Sherrington Executive Vice President, Business | 272.8K | — | — | 201.2K | 57.3K | 21.6K | 552.8K | 36.39% | ↗ |
| 52 | 2017 | James R. Empfield Senior Vice President, Drug Discovery of Xenon Pharmaceuticals USA Inc. | 249.7K | — | — | 221.6K | 59.9K | 13.8K | 545.0K | 40.66% | ↗ |
| 53 | 2016 | Simon N. Pimstone President and Chief Executive Officer | 326.3K | — | — | 251.0K | 114.2K | 25.5K | 717.0K | 35.01% | ↗ |
| 54 | 2016 | Simon N. Pimstone Chief Executive Officer | 326.3K | — | — | 251.0K | 114.2K | 25.5K | 717.0K | 35.01% | ↗ |
| 55 | 2016 | Ian C. Mortimer Chief Financial Officer, Chief Operating Officer and Corporate Secretary | 261.4K | — | — | 200.8K | 73.2K | 19.5K | 554.8K | 36.19% | ↗ |
| 56 | 2016 | Ian C. Mortimer President, Chief Financial Officer and Corporate Secretary | 261.4K | — | — | 200.8K | 73.2K | 19.5K | 554.8K | 36.19% | ↗ |
| 57 | 2016 | James R. Empfield Senior Vice President, Drug Discovery of Xenon Pharmaceuticals USA Inc. | 215.9K | 50.0K | — | 181.2K | 60.2K | 23.7K | 531.1K | 34.12% | ↗ |
| 58 | 2016 | Robin P. Sherrington Senior Vice President, Business | 239.3K | — | — | 100.4K | 58.6K | 20.8K | 419.1K | 23.95% | ↗ |
| 59 | 2016 | Robin P. Sherrington Executive Vice President, Business | 239.3K | — | — | 100.4K | 58.6K | 20.8K | 419.1K | 23.95% | ↗ |
| 60 | 2016 | Y. Paul Goldberg Senior Vice President, Clinical Development | 239.8K | — | — | 100.4K | 56.2K | 20.4K | 416.8K | 24.09% | ↗ |
| 61 | 2015 | Simon N. Pimstone President and Chief Executive Officer | 328.9K | — | — | 1.34M | 105.2K | 24.7K | 1.80M | 74.47% | ↗ |
| 62 | 2015 | Simon N. Pimstone Chief Executive Officer | 328.9K | — | — | 1.34M | 105.2K | 24.7K | 1.80M | 74.47% | ↗ |
| 63 | 2015 | Ian C. Mortimer Chief Financial Officer, Chief Operating Officer and Corporate Secretary | 256.2K | — | — | 784.3K | 65.5K | 18.2K | 1.12M | 69.77% | ↗ |
| 64 | 2015 | Ian C. Mortimer President, Chief Financial Officer and Corporate Secretary | 256.2K | — | — | 784.3K | 65.5K | 18.2K | 1.12M | 69.77% | ↗ |
| 65 | 2015 | Karen G. Corraini Former General Counsel and Corporate Secretary | 106.0K | 3.2K | — | 416.9K | — | 445.2K | 971.3K | 42.92% | ↗ |
| 66 | 2015 | Y. Paul Goldberg Vice President, Clinical Development | 242.1K | 1.9K | — | 494.4K | 54.1K | 13.9K | 806.4K | 61.31% | ↗ |
| 67 | 2015 | Y. Paul Goldberg Senior Vice President, Clinical Development | 242.1K | 1.9K | — | 494.4K | 54.1K | 13.9K | 806.4K | 61.31% | ↗ |
| 68 | 2015 | Robin P. Sherrington Senior Vice President, Business | 232.5K | — | — | 494.4K | 52.0K | 19.5K | 798.4K | 61.92% | ↗ |
| 69 | 2015 | Robin P. Sherrington Executive Vice President, Business | 232.5K | — | — | 494.4K | 52.0K | 19.5K | 798.4K | 61.92% | ↗ |
| 70 | 2015 | Charles J. Cohen Vice President, Biology | 203.2K | 2.2K | — | 494.4K | 49.2K | 17.5K | 766.5K | 64.50% | ↗ |
| 71 | 2014 | Simon N. Pimstone President and Chief Executive Officer | 355.2K | — | — | 196.4K | 177.6K | 21.8K | 751.1K | 26.15% | ↗ |
| 72 | 2014 | Simon N. Pimstone President and Chief Executive Officer | 355.2K | — | — | 196.4K | 177.6K | 21.8K | 751.1K | 26.15% | ↗ |
| 73 | 2014 | Ian C. Mortimer Chief Financial Officer | 281.8K | — | — | 176.1K | 112.7K | 17.3K | 587.8K | 29.96% | ↗ |
| 74 | 2014 | Ian C. Mortimer Chief Financial Officer, Chief Operating Officer and Corporate Secretary | 281.8K | — | — | 176.1K | 112.7K | 17.3K | 587.8K | 29.96% | ↗ |
| 75 | 2014 | Y. Paul Goldberg Vice President, Clinical Development | 271.2K | — | — | 55.4K | 94.9K | 15.6K | 437.1K | 12.68% | ↗ |
| 76 | 2014 | Y. Paul Goldberg Vice President, Clinical Development | 271.2K | — | — | 55.4K | 94.9K | 15.6K | 437.1K | 12.68% | ↗ |
| 77 | 2014 | Y. Paul Goldberg Senior Vice President, Clinical Development | 271.2K | — | — | 55.4K | 94.9K | 15.6K | 437.1K | 12.68% | ↗ |
| 78 | 2014 | Karen G. Corraini Former General Counsel and Corporate Secretary | 236.7K | — | — | 63.4K | 82.8K | 20.9K | 403.9K | 15.70% | ↗ |
| 79 | 2014 | Karen G. Corraini General Counsel and Corporate Secretary | 236.7K | — | — | 63.4K | 82.8K | 20.9K | 403.9K | 15.70% | ↗ |
| 80 | 2014 | Robin P. Sherrington Senior Vice President, Business | 231.3K | — | — | 56.8K | 81.0K | 16.0K | 385.0K | 14.74% | ↗ |
| 81 | 2014 | Robin Sherrington Senior Vice President of Business Corporate Development | 231.3K | — | — | 56.8K | 81.0K | 16.0K | 385.0K | 14.74% | ↗ |
| 82 | 2014 | Charles J. Cohen Vice President, Biology | 219.2K | — | — | 27.1K | 65.8K | 14.3K | 326.3K | 8.30% | ↗ |
| 83 | 2013 | Simon N. Pimstone President and Chief Executive Officer | 369.9K | — | — | 274.9K | 115.6K | 20.6K | 781.0K | 35.20% | ↗ |
| 84 | 2013 | Simon N. Pimstone President and Chief Executive Officer | 369.9K | — | — | 274.9K | 115.6K | 20.6K | 781.0K | 35.20% | ↗ |
| 85 | 2013 | Y. Paul Goldberg Vice President, Clinical Development | 281.0K | 3.5K | — | 51.5K | 59.0K | 16.2K | 411.2K | 12.52% | ↗ |
| 86 | 2013 | Y. Paul Goldberg Vice President, Clinical Development | 281.0K | 3.5K | — | 51.5K | 59.0K | 16.2K | 411.2K | 12.52% | ↗ |
| 87 | 2013 | Karen G. Corraini General Counsel and Corporate Secretary | 244.1K | 3.5K | — | 71.3K | 68.7K | 13.5K | 401.1K | 17.77% | ↗ |
| 88 | 2013 | Karen G. Corraini Former General Counsel and Corporate Secretary | 244.1K | 3.5K | — | 71.3K | 68.7K | 13.5K | 401.1K | 17.77% | ↗ |
| 89 | 2013 | Robin P. Sherrington Senior Vice President, Business | 234.0K | 3.5K | — | 67.4K | 57.3K | 13.8K | 376.0K | 17.91% | ↗ |
| 90 | 2013 | Robin Sherrington Senior Vice President of Business Corporate Development | 234.0K | 3.5K | — | 67.4K | 57.3K | 13.8K | 376.0K | 17.91% | ↗ |
| 91 | 2013 | Ian C. Mortimer Chief Financial Officer, Chief Operating Officer and Corporate Secretary | 64.2K | 9.7K | — | 253.2K | 19.7K | 3.4K | 350.3K | 72.30% | ↗ |
| 92 | 2013 | Ian C. Mortimer Chief Financial Officer | 64.2K | 9.7K | — | 253.2K | 19.7K | 3.4K | 350.3K | 72.30% | ↗ |
| 93 | 2013 | Charles J. Cohen Vice President, Biology | 221.7K | — | — | 12.0K | 55.4K | 12.3K | 301.5K | 3.98% | ↗ |
| 94 | 2012 | Simon N. Pimstone President and Chief Executive Officer | 366.4K | 100.1K | — | 71.8K | 183.2K | 20.5K | 741.8K | 9.68% | ↗ |
| 95 | 2012 | Y. Paul Goldberg Vice President, Clinical Development | 278.4K | 25.0K | — | 9.5K | 83.5K | 16.1K | 412.4K | 2.30% | ↗ |
| 96 | 2012 | Karen G. Corraini General Counsel and Corporate Secretary | 235.0K | 50.0K | — | 19.1K | 70.5K | 13.1K | 387.7K | 4.92% | ↗ |
| 97 | 2012 | Robin Sherrington Senior Vice President of Business Corporate Development | 229.6K | 50.0K | — | 17.2K | 68.9K | 13.6K | 379.3K | 4.53% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ian C. Mortimer | President, Chief Executive Officer, Principal Accounting Officer & Director | 1M | male |
| Christopher John Kenney | Chief Medical Officer | 848.7K | — |
| Andrea DiFabio | Chief Legal Officer & Corporate Secretary | 766.2K | female |
| Darren S. Cline | Chief Commercial Officer | 619.8K | male |
| Robin Sherrington | Executive Vice President of Strategy & Innovation | 587.0K | — |
| Thomas Patrick Kelly | Chief Financial Officer | 515.7K | male |
| James R. Empfield | Executive Vice President of Drug Discovery | 323.4K | — |
| Matthew D. Ronsheim | Chief Operating Officer | — | — |
| Gilbert | Senior Director | — | — |
| Shelley McClCoskey | Executive Vice President of Human Resources | — | female |
| Shelley McCloskey | Executive Vice President of Human Resources | — | female |
| Colleen Alabiso | Senior Vice President of Corporate Affairs | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for XENE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
